• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Emergency

Pre-treatment and post-treatment factors may explain discrepancies between functional outcomes and follow-up imaging infarct volume after acute ischemic stroke

byJake EngelandMichael Pratte
November 12, 2021
in Emergency, Imaging and Intervention, Neurology
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Discrepancies between follow-up imaging infarct volume and functional outcomes were associated with differences in baseline characteristics and post-stroke complications among acute ischemic stroke patients with large vessel occlusions who received endovascular thrombectomy.

2. Control of post-stroke complications, such as blood pressure, glucose, and hemoglobin levels, may improve long-term functional outcomes among acute ischemic stroke patients.

Evidence Rating Level: 2 (Good)

Study Rundown: Acute ischemic strokes can lead to poor functional outcomes. Follow-up imaging infarct volume (FIV) is measured 24-48 hours after a stroke and is associated with functional outcomes at 90 days. The modified Rankin Scale (mRS) is used to assess outcomes in patients with large-vessel occlusion strokes. However, recent evidence demonstrated that FIV was not a great predictor of mRS score as FIV was only modestly correlated with long-term outcomes. The ESCAPE trial showed that 1/8 patients had discrepancies between FIV and mRS at 90 days post-stroke. This cohort study, a post-hoc analysis of the ESCAPE-NA1 randomized controlled trial, investigated the factors leading to the discrepancies between FIV and functional outcomes among patients who received endovascular thrombectomy for ischemic stroke management. Among patients with a small FIV (<25th percentile), those with mRS score >3 were classified as discrepant and those with mRS score 0-2 were non-discrepant. Among patients with a large FIV (>75th percentile), those with mRS score 0-2 were classified as discrepant and patients with mRS score >3 were non-discrepant. First, small FIV (<25th percentile) patients were examined. The discrepant group was more likely to be older, have pre-existing cancer, have more vascular risk factors, and be less likely to have a pre-stroke mRS score of 0. Furthermore, discrepant cases demonstrated lower hemoglobin and hematocrit values at 24 hours post-stroke, higher 24- and 48-hour post-stroke National Institutes of Health Stroke Score (NIHSS), and more serious adverse events (SAEs). Next, large FIV patients (>75th percentile) were assessed. The discrepant group was more likely to be younger, have lower systolic blood pressure (SBP), be less likely to have pre-existing diabetes, and have higher hemoglobin. Additionally, they had lower 24- and 48-hour post-stroke NIHSS, lower SBP, lower glucose, higher hemoglobin, and fewer SAEs among treatment-related and post-treatment variables. Overall, the discrepancies found between FIV and functional outcomes were related to differences in baseline characteristics, such as age and co-morbidities, and post-stroke complications. It is important to consider that scanner (MRI vs CT) and protocol differences at the various sites may have affected the FIV calculations.

Click to read the study in JAMA Network Open

Relevant Reading: Intra-arterial therapy and post-treatment infarct volumes: Insights from the ESCAPE randomized controlled trial

RELATED REPORTS

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

FDA approvedFor ischemic stroke: Sunharbo (asundexian), Nov 9, 2026→

In-Depth [retrospective cohort]: This study was a post-hoc analysis of the ESCAPE-NA1 double-blind, randomized, placebo-controlled clinical trial that included 48 hospitals from 8 countries. Patients were eligible if they suffered from an acute ischemic stroke due to a large vessel occlusion within 12 hours from the last known time of being well. Patients were enrolled from March 1, 2017, until August 12, 2019, and follow-up was 90-days post-stroke. Functional outcomes were assessed with the mRS score. A mRS score of 0-2 is classified as a good outcome and a mRS score of >3 is classified as a poor outcome. Among 1091 patients with FIV and 90-day mRS scores, 287 were in the <25th percentile and 275 were in the >75th percentile. Discrepant groups were those with an mRS score >3 in the <25th percentile cohort (small FIV but high mRS) and patients with an mRS score 0-2 in the >75th percentile cohort (large FIV but low mRS). This study utilized two models for analysis: a) the model with prespecified variables based on the ESCAPE trial analysis, and b) a model with variables selected by multivariable logistic regression. The outcomes of this study were whether the models could assess whether prespecified factors can identify patients with small FIV and high mRS and large FIV with low mRS. Baseline characteristics, outcomes, treatments, and serious adverse events (infarct in new territory [INT], recurrent stroke, pneumonia, CHF) were compared between discrepant and non-discrepant groups. Upon assessment of the discrepant group in small FIV patients, pre-treatment factors, such as age (adjusted odds ratio [aOR]: 1.08 [95% CI: 1.04-1.13]), cancer (aOR: 61.65 [95% CI: 2.91-1304.27]), and vascular risk factors (aOR: 1.30 [95% CI: 1.06-1.59]), and post-treatment factors, such as SAE (aOR: 3.46 [95% CI: 1.72-6.96]) and hemoglobin level at 24 hours (aOR: 0.97 [95% CI: 0.91-0.96]) were significantly different compared to the non-discrepant group. Upon assessment of the discrepant group in large FIV patients, pre-treatment characteristics, including age (aOR: 0.97 [95% CI: 0.95-0.99]) and pre-existing diabetes (aOR: 0.38 [95% CI: 0.16-0.92]), and post-treatment factors, such as SAE (aOR: 0.13 [95% CI: 0.05-0.30]), stroke progression (aOR: 0.05 [95% CI: 0.01-0.25]), and hemoglobin level at 24 hours (aOR: 1.02 [95% CI: 1.01-1.04]) were significantly different compared to the non-discrepant group.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: embolic strokeischemic strokestrokestroke complicationsstroke recovery
Previous Post

#VisualAbstract Melanomas diagnosed through routine skin checks were associated with significantly lower mortality rates

Next Post

Intravenous iron associated with increased infection risk compared to oral or no iron

RelatedReports

TIA collage: a calm older man, a neck artery traced by a teal ribbon, an hourglass and folded reading glasses
2MM Trial Briefs

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

November 10, 2026
Stroke treatment collage: an engraved brain with teal arteries and one blocked branch, a coiled catheter and a stopwatch
Emergency

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

November 7, 2026
Cannabis and mental health collage: a thoughtful young man with curly hair, a flat cannabis leaf and three blank shopfronts
Cardiology

Cannabis use, including smoked or edible, linked to higher stroke risk

November 6, 2026
A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Next Post

Intravenous iron associated with increased infection risk compared to oral or no iron

2 Minute Medicine Rewind November 15, 2021

Cognitive-behavioural therapy alternating between face-to-face and online module sessions effective for treating anxiety disorders

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.